BRAINSTORM CELL THERAPEUTICS (BCLI)

Company Profile

Brainstorm Cell Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in New York City, New York and currently employs 29 full-time employees. The company went IPO on 2003-05-28. BrainStorm Cell Therapeutics Inc. is a developer of autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The neurodegenerative diseases include Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), Alzheimer’s disease (AD), and others. The firm is engaged in the clinical development and commercialization of the NurOwn technology platform used to produce autologous mesenchymal stem cells- neurotrophic factors (MSC-NTF) cells. NurOwn leverages cell culture methods to induce autologous bone marrow derived MSCs to secrete high levels of NTFs, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. Autologous MSC-NTF cells is for the treatment of ALS. The company has completed a phase III trial in ALS. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd., holds exclusive rights to commercialize NurOwn technology.

Company Info

BRAINSTORM CELL THERAPEUTICS

1325 Avenue Of Americas, 28th Floor

New York City NEW YORK 10019

P: 12014880460

CEO: Chaim Lebovits

Employees: 29

Website: https://brainstorm-cell.com/